Form 4: OptimizeRx Director Vos Ellen O'Connor Reports Stock Transactions

Director Vos Ellen O'Connor reports acquisition and disposal of OptimizeRx Corp (OPRX) common stock and restricted stock units.

Summary

• On June 5, 2024, Director Vos Ellen O'Connor exercised 10,061 restricted stock units (RSUs) converting them into common stock.
• Also on June 5, 2024, O'Connor disposed of 10,061 shares of common stock.
• On June 7, 2024, O'Connor was granted 13,286 restricted stock units that will vest on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of shareholders.
• Following these transactions, O'Connor beneficially owns 62,774 shares of OptimizeRx common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Positives

• The grant of restricted stock units to a director aligns their interests with the company's long-term performance.

Future Outlook

The restricted stock units granted on June 7, 2024, will vest on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of shareholders.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the actions of company leadership.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a director.

Key Dates